Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
Sci Rep ; 11(1): 23277, 2021 12 02.
Artigo em Inglês | MEDLINE | ID: mdl-34857853

RESUMO

The aim of this study was to evaluate renal hemodynamics, routine clinical and laboratory parameters used to estimate renal function, and clinical evolution during six months in bitches with mammary carcinomas that underwent mastectomy and were treated (TG) or not (CG) with carprofen for three months after surgery. Twenty-six bitches with mammary carcinoma were equally distributed into TG that received carprofen 4.4 mg/kg/day for 90 days and CG that did not receive anti-inflammatory medication. Renal artery Doppler flowmetry, contrast-enhanced ultrasound (CEUS) of renal parenchyma, haematological, biochemical and clinical analyses were obtained once a month. These data were compared between groups and time via analysis of variance (ANOVA) in a completely randomized design with repeated measures (P < 0.05). On B-mode ultrasound, the area of the renal artery was greater (P = 0.0003) in the TG. Regarding laboratory findings, haematocrit and haemoglobin were similar in both groups, showing a significant and gradual increase after three months of treatment; MCV, MHC, and MCHC were increased (P < 0.05) and lymphocyte and band counts decreased (P < 0.05) in the TG. Regarding biochemical tests, ALT was the only parameter with a significant difference, being higher (P = 0.0272) in the treated group. It can be concluded that the use of carprofen for 90 days causes minimal changes in renal perfusion, erythrocyte parameters and ALT activity, and reduces the proportion of blood inflammatory cells. Therefore, use of this medication can be carried out safely in patients who require auxiliary cancer treatment.


Assuntos
Carbazóis/administração & dosagem , Carbazóis/efeitos adversos , Carcinoma/tratamento farmacológico , Doenças do Cão/tratamento farmacológico , Rim/irrigação sanguínea , Rim/diagnóstico por imagem , Neoplasias Mamárias Animais/tratamento farmacológico , Circulação Renal/efeitos dos fármacos , Ultrassonografia Doppler , Animais , Carcinoma/fisiopatologia , Carcinoma/cirurgia , Doenças do Cão/fisiopatologia , Doenças do Cão/cirurgia , Cães , Feminino , Glândulas Mamárias Animais/cirurgia , Neoplasias Mamárias Animais/fisiopatologia , Neoplasias Mamárias Animais/cirurgia , Fatores de Tempo
2.
Eur J Surg Oncol ; 44(7): 983-990, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29530346

RESUMO

BACKGROUND: The aim was to compare health-related quality-of-life (HRQOL) and cost-effectiveness between cytoreductive surgery with intraperitoneal chemotherapy (CRS + IPC) and systemic chemotherapy for patients with colorectal peritoneal metastases. METHODS: Patients included in the Swedish Peritoneal Trial comparing CRS + IPC and systemic chemotherapy completed the EORTC QLQ-C30 and SF-36 questionnaires at baseline, 2, 4, 6, 12, 18, and 24 months. HRQOL at 24 months was the primary endpoint. EORTC sum score, SF-36 physical and mental component scores at 24 months were calculated and compared for each arm and then referenced against general population values. Two quality-adjusted life-year (QALY) indices were applied (EORTC-8D and SF-6D) and an incremental cost-effectiveness ratio (ICER) per QALY gained was calculated. A projected life-time ICER per QALY gained was calculated using predicted survival according to Swedish population statistics. RESULTS: No statistical differences in HRQOL between the arms were noted at 24 months. Descriptively, survivors in the surgery arm had higher summary scores than the general population at 24 months, whereas survivors in the chemotherapy arm had lower scores. The projected life-time QALY benefit was 3.8 QALYs in favor of the surgery arm (p=0.06) with an ICER per QALY gained at 310,000 SEK (EORTC-8D) or 362,000 SEK (SF-6D) corresponding to 26,700-31,200 GBP. CONCLUSION: The HRQOL in patients with colorectal peritoneal metastases undergoing CRS + IPC appear similar to those receiving systemic chemotherapy. Two-year survivors in the CRS + IPC arm have comparable HRQOL to a general population reference. The treatment is cost-effective according to NICE guidelines.


Assuntos
Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma/terapia , Neoplasias Colorretais/terapia , Procedimentos Cirúrgicos de Citorredução/métodos , Fluoruracila/administração & dosagem , Hipertermia Induzida/métodos , Neoplasias Peritoneais/terapia , Qualidade de Vida , Idoso , Antineoplásicos/economia , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Carcinoma/fisiopatologia , Carcinoma/psicologia , Carcinoma/secundário , Neoplasias Colorretais/patologia , Neoplasias Colorretais/fisiopatologia , Neoplasias Colorretais/psicologia , Análise Custo-Benefício , Procedimentos Cirúrgicos de Citorredução/economia , Feminino , Fluoruracila/economia , Nível de Saúde , Humanos , Hipertermia Induzida/economia , Infusões Parenterais , Masculino , Pessoa de Meia-Idade , Compostos Organoplatínicos/administração & dosagem , Compostos Organoplatínicos/economia , Oxaliplatina , Neoplasias Peritoneais/fisiopatologia , Neoplasias Peritoneais/psicologia , Neoplasias Peritoneais/secundário , Anos de Vida Ajustados por Qualidade de Vida
3.
Thyroid ; 27(8): 1034-1042, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28474541

RESUMO

BACKGROUND: Differentiated thyroid cancer (DTC) has a good prognosis but a remaining risk of recurrence, and life-long follow-up as well as medication with levothyroxine may be necessary. The aim of this study was to clarify how thyroid-related symptoms affect health-related quality of life (HRQoL) 14-17 years after diagnosis in Swedish DTC patients. METHODS: From the all-encompassing population-based Swedish Cancer Registry, 353 patients diagnosed with DTC during 1995-1998 were identified and invited to answer a study-specific questionnaire and the HRQoL questionnaire SF-36 14-17 years after their diagnosis. Subgroups were studied according to thyroid-related symptoms, both symptoms correlated to thyroid disease or levothyroxine treatment and side effects from surgery and radioiodine treatment. RESULTS: Of the patients with DTC, 279 (79%) answered the questionnaires. In all, only 19 (7%) reported a recurrence. Patients with one single symptom (e.g., fatigue, sleeping disorders, irritability, lower stress resistance, muscle weakness, bodily restlessness, sweating, palpitations, or flushes) had significantly lower HRQoL measured with the SF-36 compared to those without that specific symptom (p < 0.001). Furthermore, those 238 patients with at least one symptom, regardless of which one, had significantly lower HRQoL in all eight SF-36 domains compared to patients that no thyroid symptom (n = 34; p < 0.001). In seven patients, the questionnaires were not complete in terms of the thyroid-related questions. The association between thyroid symptoms and lower HRQoL remained after adjusting for age, sex, comorbidities, education, and menopause. CONCLUSIONS: DTC patients reporting thyroid symptoms scored lower in HRQoL compared to those with no symptoms >14 years after diagnosis.


Assuntos
Carcinoma/fisiopatologia , Efeitos Psicossociais da Doença , Fadiga/etiologia , Qualidade de Vida , Transtornos do Sono-Vigília/etiologia , Estresse Psicológico/etiologia , Neoplasias da Glândula Tireoide/fisiopatologia , Adulto , Carcinoma/patologia , Carcinoma/prevenção & controle , Carcinoma/terapia , Diferenciação Celular , Estudos de Coortes , Terapia Combinada/efeitos adversos , Estudos Transversais , Fadiga/epidemiologia , Fadiga/prevenção & controle , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , Sistema de Registros , Risco , Autorrelato , Transtornos do Sono-Vigília/epidemiologia , Transtornos do Sono-Vigília/prevenção & controle , Estresse Psicológico/epidemiologia , Estresse Psicológico/prevenção & controle , Suécia/epidemiologia , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/prevenção & controle , Neoplasias da Glândula Tireoide/terapia
4.
J Health Psychol ; 22(4): 397-408, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-26349615

RESUMO

The study examined whether the items of the World Health Organization Quality of Life-Brief questionnaire can assess its four underlying domains (Physical, Psychological, Social, and Environment) in a sample of lung cancer patients. All patients ( n = 1150) were recruited from a medical center in Tainan, and each participant completed the World Health Organization Quality of Life-Brief. Several Rasch rating scale models were used to examine the data-model fit, and Rasch analyses corroborated that each domain of the World Health Organization Quality of Life-Brief could be unidimensional. Although three items were found to have a poor fit, all the other items fit the unidimensionality with ordered thresholds.


Assuntos
Carcinoma , Indicadores Básicos de Saúde , Neoplasias Pulmonares , Modelos Estatísticos , Qualidade de Vida , Adulto , Idoso , Carcinoma/fisiopatologia , Carcinoma/psicologia , Feminino , Humanos , Neoplasias Pulmonares/fisiopatologia , Neoplasias Pulmonares/psicologia , Masculino , Pessoa de Meia-Idade , Psicometria , Qualidade de Vida/psicologia , Reprodutibilidade dos Testes , Organização Mundial da Saúde
7.
Clin Nutr ; 32(1): 65-72, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22695408

RESUMO

BACKGROUND & AIMS: Different nutrition assessment tools and definitions are proposed for cancer-associated malnutrition and wasting (cachexia). We studied the associations between these assessments and overall survival in stage IV colorectal carcinoma patients. METHODS: Anthropometric measures, energy intake, biochemical variables, nutritional risk screening, assessment of malnutrition, cachexia and body composition from computed tomography images were analysed, in 77 patients from Norway and Canada. Results were dichotomized into presence or absence of nutritional risk, malnutrition, cachexia and sarcopenia (low muscle mass) and associated with survival. RESULTS: Overall, 22% up to 55% of the patients had cachexia according to different cachexia criteria: 34% were malnourished, 42% were at nutritional risk, and 39% were sarcopenic. Forty-four percent of the patients did not meet criteria for any of these conditions. Patients with cachexia defined by Cancer Cachexia Study Group (CCSG) had shorter survival in an unadjusted analysis, [Hazard ratio (HR) = 2.43; 95% confidence interval (CI) 1.32-4.47; P = 0.005]. After adjusting for nation, age and gender, cachexia (HR = 2.26; CI 1.18-4.32; P = 0.014) and malnutrition (HR = 1.83; CI 1.06-3.13; P = 0.029) remained significant predictors of survival. CONCLUSIONS: Nutritional depletion in up to 55% of the patients was found. The lack of concordance between the results obtained by different assessment criteria was obvious. CCSG's cachexia score was the best prognostic factor for overall survival.


Assuntos
Caquexia/epidemiologia , Carcinoma/fisiopatologia , Neoplasias Colorretais/fisiopatologia , Avaliação Nutricional , Estado Nutricional , Adulto , Idoso , Idoso de 80 Anos ou mais , Caquexia/diagnóstico , Caquexia/etiologia , Caquexia/fisiopatologia , Canadá/epidemiologia , Carcinoma/diagnóstico , Carcinoma/patologia , Estudos de Coortes , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/patologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Noruega/epidemiologia , Prevalência , Prognóstico , Índice de Gravidade de Doença , Análise de Sobrevida , Adulto Jovem
8.
Cancer ; 118(5): 1457-65, 2012 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-21837676

RESUMO

BACKGROUND: The objective of this international field study was to test the reliability, validity, and responsiveness of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BM22 module to assess health-related quality of life (HRQOL) in patients with bone metastases. METHODS: Patients undergoing a variety of bone metastases-specific treatments were accrued. The QLQ-BM22 was administered with the QLQ-C30 at baseline and at 1 follow-up time point internationally. A debriefing questionnaire was administered to determine patient acceptability and understanding. RESULTS: Large-scale field testing of the QLQ-BM22 in addition to the QLQ-C30 took place in 7 countries: Brazil, Canada, Cyprus, Egypt, France, India, and Taiwan. A total of 400 patients participated. Multitrait scaling analyses confirmed 4 scales in the 22-item module. The scales were able to discriminate between clinically distinct patient groups, such as between those with a poor and those with a better performance status. The QLQ-BM22 was well received in all 7 countries, and the majority of patients did not recommend any significant changes from the module in its current form. CONCLUSIONS: The final QLQ-BM22 module contains 22 items and 4 scales assessing Painful Sites, Painful Characteristics, Functional Interference, and Psychosocial Aspects. Results confirmed the validity, reliability, cross-cultural applicability, and sensitivity of the 22-item EORTC QLQ-BM22. It is therefore recommended that the QLQ-BM22 be used in addition to the QLQ-C30 in clinical trials to assess HRQOL in patients with bone metastases.


Assuntos
Neoplasias Ósseas/secundário , Carcinoma/secundário , Indicadores Básicos de Saúde , Qualidade de Vida , Inquéritos e Questionários , Adulto , Idoso , Neoplasias Ósseas/diagnóstico , Neoplasias Ósseas/fisiopatologia , Neoplasias Ósseas/psicologia , Carcinoma/diagnóstico , Carcinoma/fisiopatologia , Carcinoma/psicologia , Feminino , Geografia , Nível de Saúde , Humanos , Internacionalidade , Masculino , Oncologia/métodos , Oncologia/organização & administração , Pessoa de Meia-Idade , Prognóstico , Qualidade de Vida/psicologia , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Sociedades Médicas
9.
Indian J Cancer ; 48(4): 428-37, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22293256

RESUMO

BACKGROUND: Breast cancer is associated with substantial medical and economic burden. This study assisted the expenditure incurred by the subjects on diagnosis and treatment till the period of follow-up. MATERIALS AND METHODS: This is a prospective study; a case series of patients studied at the time of diagnosis and followed after 6 months. The study was conducted at one of Hospitals in India, from January 2006 to December 2007. One hundred and seventy-two women with new primary breast cancer were included in the study. During the study period 69 subjects were lost to follow-up. The comparative analysis was done for 103 subjects. Cost implications of breast cancer include direct medical costs and indirect costs. Questionnaire for the data collection was used. Descriptive statistics and correlation analysis were used. RESULTS: The median total direct and indirect expenditure was Rs. 12,100 (US$ 1 = Rs 50) with the range of Rs. 0-54000. The largest component of total direct medical costs was in stage I (median Rs. 6530), total indirect costs (median Rs. 7500), and median total cost was Rs. 17,600. The total expenditures (median Rs. 13,100) were the highest in younger age group (<40). The median direct expenditure was higher in the subjects who visited private setup before coming to Hospital (Rs. 8250) than those who came directly (Rs. 4500). CONCLUSIONS: Cost of treatment for breast cancer depends on many factors, including the stages of the cancer, the woman's age, perhaps the costs of treatment, private hospital and insurance.


Assuntos
Neoplasias da Mama/economia , Carcinoma/economia , Auditoria Clínica , Gastos em Saúde/estatística & dados numéricos , Seguro , Adulto , Fatores Etários , Idoso , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/patologia , Neoplasias da Mama/fisiopatologia , Carcinoma/epidemiologia , Carcinoma/patologia , Carcinoma/fisiopatologia , Feminino , Seguimentos , Hospitais , Humanos , Índia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Prospectivos , Prevenção Terciária
10.
Srp Arh Celok Lek ; 135(5-6): 286-92, 2007.
Artigo em Sérvio | MEDLINE | ID: mdl-17633314

RESUMO

INTRODUCTION: Lung resection in patients with limited lung function is one of the greatest challenges in general thoracic surgery. OBJECTIVE: The aim of the study was to analyse the pattern of lung function changes after operation, operative morbidity and mortality and to compare them with control group of patients. METHOD: The study included 34 patients with limited lung function, operated for primary lung cancer in one-year period. All patients underwent preoperative desobstructive treatment. The type of ventilatory disorder was analysed depending on preoperative radiographic and bronchoscopic aspect. STATISTICS: chi-square test, t-test. RESULTS: In patients with lobectomy, the mean difference in forced expiratory volume in the first second (FEV1) between preoperative and postoperative values was 16.81%, whilst in the pneumonectomy group this difference was 39.51%. The mean change in forced vital capacity (FVC) in the lobectomy and pneumonectomy group was 15.83% and 42.73% respectively. In the control group of 28 patients with lobectomy, the decrease in FVC and FEV1 was 19.9% and 24.18% respectively. In the control group of 28 patients with pneumonectomy, the decrease in FVC and FEV1 was 43.52% and 41.36% respectively. In patients with limited lung function and lobectomy, changes in FEV1 and VC after resection were significantly lower compared to the control group of patients with lobectomy and normal lung function. None of 34 operated patients with borderline lung function died inside 30 postoperative days. In the same period, of a total number of 344 patients without respiratory function impairement, operative mortality was 3.1%. In the analysed group, operative morbidity was 32.35%. Cardiovascular and respiratory complications in the analysed and control groups occurred in 14.7% and 6.1% of patients respectively (p > 0.05). CONCLUSION: Surgery should not be excluded in patients with borderline lung function prior to preoperative treatment and additional lung function assessment.


Assuntos
Carcinoma/cirurgia , Neoplasias Pulmonares/cirurgia , Idoso , Carcinoma/mortalidade , Carcinoma/fisiopatologia , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/fisiopatologia , Masculino , Pessoa de Meia-Idade , Pneumonectomia/mortalidade , Ventilação Pulmonar , Taxa de Sobrevida
11.
Invest Radiol ; 41(9): 691-6, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16896304

RESUMO

OBJECTIVE: We describe the effects of tumor necrosis factor alpha (TNFalpha) on tumor microvasculature in a murine colon carcinoma model using serial dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). MATERIAL AND METHODS: Mice with subcutaneous murine colon carcinomas (MC-38) were imaged at 4.7 T after administration of 0.2 mmol/kg gadolinium-DTPA. Both treated and control mice (each group, n = 4), were scanned at baseline and 2, 4, 6, and 96 hours. A 2-compartment pharmacokinetic model generated parameters such as K, kep, and initial area under the gadolinium concentration curve (IAUC). RESULTS: The treatment group revealed significant differences in K at all time points after TNFalpha. kep and IAUC were significantly reduced at 2, 6, and 96 hours. The coefficient of variation in control animals ranged from 0.13 for IAUC to 0.30 for K. Mild histologic changes were observed at 2 to 6 hours, but considerable central necrosis with a vascular tumor rim was seen at 96 hours. CONCLUSION: DCE MRI can be used to detect early effects of TNFalpha. Serial DCE MRI is a promising tool in assessing the early effects of antivascular therapies.


Assuntos
Carcinoma/diagnóstico , Neoplasias do Colo/diagnóstico , Meios de Contraste , Aumento da Imagem , Imageamento por Ressonância Magnética/métodos , Fator de Necrose Tumoral alfa/uso terapêutico , Animais , Capilares/efeitos dos fármacos , Carcinoma/tratamento farmacológico , Carcinoma/fisiopatologia , Linhagem Celular Tumoral , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/fisiopatologia , Modelos Animais de Doenças , Camundongos , Camundongos Endogâmicos C57BL , Valores de Referência
13.
J Behav Med ; 27(5): 425-44, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15675633

RESUMO

Fatigue is a common and debilitating symptom often experienced during and following cancer treatment. An Ecological Momentary Assessment (EMA) approach was used to examine the diurnal pattern of off-treatment fatigue in breast cancer survivors. Twenty-five breast cancer (BC) survivors 6-26 months posttreatment and age-matched groups of healthy women (HC; n = 25) and women with benign breast problems (BBP; n = 24) completed four daily diary measures of fatigue, pain, and mood for 5 consecutive days. Type of activity engaged in at the time of the diary assessments, as well as daily pedometer activity level, and nightly sleep duration were also assessed. While BC survivors reported greater levels of fatigue relative to BBP anid HC groups, no group differences in mood, activity type or level, sleep duration, or diurnal pattern of fatigue were evident. The results confirm that fatigue mav continue to be experienced long after conclusion of cancer treatment while questioning its clinical significance, provide insight into potential etiological mechanisms underlying off-treatment fatigue in, and demonstrate the value of EMA approaches to the study of cancer-related fatigue.


Assuntos
Neoplasias da Mama/fisiopatologia , Carcinoma/fisiopatologia , Fadiga/etiologia , Indicadores Básicos de Saúde , Sobreviventes/psicologia , Adulto , Afeto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Carcinoma/tratamento farmacológico , Carcinoma/radioterapia , Ritmo Circadiano , Ecologia , Fadiga/diagnóstico , Feminino , Humanos , Pessoa de Meia-Idade , Dor/diagnóstico , Dor/etiologia , Medição da Dor , Radioterapia/efeitos adversos , Inquéritos e Questionários
14.
Cytometry A ; 51(1): 1-6, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12500299

RESUMO

BACKGROUND: Repopulation of clonogenic tumor cells appears to increase during fractionated radiation treatment and is recognized as an important factor affecting local control. Given the longer intervals between cycles and longer total duration of treatment, the impact of repopulation is likely to be greater after chemotherapy. METHODS: We assessed tumor cell repopulation with the proliferative marker Ki-67 in 21 patients with ovarian carcinoma who received initial chemotherapy. Paraffin slides were evaluated from the diagnostic biopsy and from tumor obtained at debulking surgery after chemotherapy. Immunohistochemistry using the MIB-1 antibody was performed on the paired samples and analyzed with a digital imaging device linked to a color camera mounted on a transmitted-light microscope. The ratio of Ki-67 positive to all nuclei was used as a proliferative index and compared for pre- and postchemotherapy specimens. RESULTS: All patients received platinum-based chemotherapy and most showed a response to treatment. The median duration between last chemotherapy and debulking surgery was 33 days (range, 22-50 days). Four (19%) of 21 patients showed an increased proliferative index after chemotherapy, and the remainder showed a decrease (n = 12) or no significant change (n = 5). CONCLUSIONS: Our results did not suggest an increase in proliferation of tumor cells after this type of chemotherapy in the majority of patients with ovarian cancer.


Assuntos
Antineoplásicos/efeitos adversos , Carcinoma/patologia , Resistencia a Medicamentos Antineoplásicos , Recidiva Local de Neoplasia/induzido quimicamente , Recidiva Local de Neoplasia/patologia , Neoplasias Ovarianas/patologia , Biomarcadores Tumorais , Carboplatina/efeitos adversos , Carcinoma/tratamento farmacológico , Carcinoma/fisiopatologia , Divisão Celular/efeitos dos fármacos , Divisão Celular/fisiologia , Núcleo Celular/patologia , Células Clonais/citologia , Células Clonais/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Feminino , Humanos , Antígeno Ki-67 , Recidiva Local de Neoplasia/fisiopatologia , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/fisiopatologia , Paclitaxel/efeitos adversos , Projetos Piloto
15.
Br J Cancer ; 86(10): 1540-5, 2002 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-12085201

RESUMO

We investigated if a cancer patient's unrelieved symptoms during the last 3 months of life increase the risk of long-term psychological morbidity of the surviving partner. All women (n=506) living in Sweden under 80 years of age, who lost their husband/partner owing to cancer of the prostate in 1996 or of the urinary bladder in 1995 or 1996 were asked to answer an anonymous postal questionnaire, 2-4 years after their loss. The widows' psychological morbidity was associated with the patient's unrelieved mental symptoms. When the patient was perceived to have been very anxious during last three months of life (compared to no observed symptoms) the relative risks for the widows' psychological morbidity were: 2.5 (1.4-4.3) for depression and 3.4 (1.4-8.2) for anxiety. When comparing reports of the patient's pain (much vs no), the relative risks were 0.8 (0.5-1.2) for widowhood depression, and 0.8 (0.4-1.7) for widowhood anxiety. The patients were found to have had adequate access to physical pain control but poor access to psychological symptom control. Efficiency in diagnosing and treating psychological complications of terminally ill cancer patients may not only improve their quality of life but possibly also prevent long-term psychological morbidity of their surviving partners.


Assuntos
Cuidadores/psicologia , Estresse Psicológico/epidemiologia , Assistência Terminal/psicologia , Viuvez/psicologia , Adulto , Idoso , Ansiedade/epidemiologia , Ansiedade/etiologia , Luto , Carcinoma/fisiopatologia , Carcinoma/psicologia , Depressão/epidemiologia , Depressão/etiologia , Uso de Medicamentos/estatística & dados numéricos , Feminino , Acessibilidade aos Serviços de Saúde , Inquéritos Epidemiológicos , Humanos , Hipnóticos e Sedativos , Masculino , Pessoa de Meia-Idade , Manejo da Dor , Pacientes/psicologia , Neoplasias da Próstata/fisiopatologia , Neoplasias da Próstata/psicologia , Qualidade de Vida , Risco , Distúrbios do Início e da Manutenção do Sono/epidemiologia , Distúrbios do Início e da Manutenção do Sono/etiologia , Apoio Social , Fatores Socioeconômicos , Estresse Psicológico/etiologia , Inquéritos e Questionários , Suécia/epidemiologia , Tranquilizantes , Neoplasias da Bexiga Urinária/fisiopatologia , Neoplasias da Bexiga Urinária/psicologia
16.
Head Neck ; 20(2): 124-31, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9484943

RESUMO

BACKGROUND: Facial electroneurography (ENoG) is an established and reliable method for assessing neural degeneration in various conditions affecting the facial nerve. The facial nerve may be subclinically involved by parotid tumors, but estimating such involvement preoperatively may be difficult when facial function is normal. The hypothesis that preoperative ENoG: (1) can detect subclinical facial nerve degeneration as a measure of involvement by parotid tumors and (2) can predict facial nerve function following parotidectomy was prospectively evaluated in the present study. METHODS: Twenty-two patients undergoing parotidectomy for tumors were tested preoperatively with ENoG, and their facial nerve function was graded pre- and postoperatively (House-Brackmann system). Eight patients had malignant tumors and 14 benign tumors. RESULTS: In patients with malignant tumors, lower percentage of preoperative ENoG response indicated nerve involvement that was not evident on clinical examination and correlated significantly (p = .035) with postoperative facial nerve dysfunction. Preoperative ENoG reduction of greater than 80% was found in all patients whose facial nerve was infiltrated by tumor. In 14 patients with benign tumors, preoperative ENoG results had no correlation with postoperative facial function. CONCLUSIONS: In malignant tumors, even when facial function is clinically intact, a low preoperative ENoG response may predict facial nerve involvement by the tumor. The lower the preoperative ENoG response, the poorer is the expected postoperative facial nerve function. There was no such correlation in benign parotid tumors.


Assuntos
Eletrodiagnóstico , Doenças do Nervo Facial/diagnóstico , Nervo Facial/patologia , Glândula Parótida/inervação , Neoplasias Parotídeas/cirurgia , Potenciais de Ação/fisiologia , Adenoma Pleomorfo/patologia , Adenoma Pleomorfo/fisiopatologia , Adenoma Pleomorfo/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/patologia , Carcinoma/fisiopatologia , Carcinoma/cirurgia , Neoplasias dos Nervos Cranianos/diagnóstico , Neoplasias dos Nervos Cranianos/fisiopatologia , Eletrodiagnóstico/métodos , Estudos de Avaliação como Assunto , Nervo Facial/fisiopatologia , Doenças do Nervo Facial/fisiopatologia , Feminino , Seguimentos , Previsões , Humanos , Masculino , Melanoma/patologia , Melanoma/fisiopatologia , Melanoma/cirurgia , Pessoa de Meia-Idade , Invasividade Neoplásica , Degeneração Neural , Glândula Parótida/cirurgia , Neoplasias Parotídeas/patologia , Neoplasias Parotídeas/fisiopatologia , Cuidados Pré-Operatórios , Estudos Prospectivos , Resultado do Tratamento
17.
Ann Acad Med Singap ; 25(3): 405-12, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8876908

RESUMO

While the primary goal of laryngeal cancer management is to save life, the preservation of structure and function also holds a very prominent position in the decision making for this disease. Although the therapeutic options to achieve these goals exist for most patients presenting with laryngeal carcinoma, they are not applied to a significant number of patients. In this paper we will summarise some of the disagreements which exist about optimal management and demonstrate that the opinions of experts trained to treat this disease have been shaped by non-evidence based approaches. In large part the specialty of practice and the geographic location of specialists have the greatest influence on the type of treatment recommended to an individual patient with a given stage of disease; medical knowledge, or more correctly the lack of it when comparing treatment options, seems to have a lesser influence on the decision process. We will consider the principal opportunities available to attempt to resolve controversies in laryngeal cancer. The discussion will include attention to randomised clinical trials, patient preferences, economic issues, and techniques to avoid the problems of selection bias when comparing outcomes for different treatments.


Assuntos
Carcinoma/terapia , Neoplasias Laríngeas/terapia , Planejamento de Assistência ao Paciente , Equipe de Assistência ao Paciente , Carcinoma/economia , Carcinoma/patologia , Carcinoma/fisiopatologia , Tomada de Decisões , Educação Médica , Medicina Baseada em Evidências , Objetivos , Humanos , Neoplasias Laríngeas/economia , Neoplasias Laríngeas/patologia , Neoplasias Laríngeas/fisiopatologia , Laringe/patologia , Laringe/fisiopatologia , Estadiamento de Neoplasias , Avaliação de Resultados em Cuidados de Saúde , Planejamento de Assistência ao Paciente/economia , Participação do Paciente , Seleção de Pacientes , Área de Atuação Profissional , Ensaios Clínicos Controlados Aleatórios como Assunto , Viés de Seleção , Especialização
19.
No Shinkei Geka ; 21(3): 213-20, 1993 Mar.
Artigo em Japonês | MEDLINE | ID: mdl-8487924

RESUMO

Meningeal carcinomatoses (MC) have been mainly studied from the viewpoint of the analysis of intracranial pressure (ICP). From the CT findings, ten patients were divided into two groups: group I, six patients showed characteristics of MC; group II, four showed normal characteristics. Ventricular fluid pressure (VFP) was continuously measured by a controlled ventricular drainage tube using a Spectramed P-10EZ at 3.1 +/- 2.1 months after the onset of the neurological symptoms. At the same time as VFP monitoring, the CBF by 133Xe method was measured in 5 cases and RI cisternography was performed in 9 cases. "A" wave was observed in 5 cases of group I and in 3 cases of group II. "B" wave was observed in all cases of both groups. In all 10 cases, the occurrence rate of both A and B waves (ORA, ORB) were high, averaging 2.34 +/- 0.54 times/hour, 74.0 +/- 16.6% time, respectively. Mean resting pressure(R) and mean peak pressure(P) tended to be high, averaging 28.8 +/- 12.2mmHg, 58.9 +/- 13.7mmHg, respectively. Mean cerebral perfusion pressure corresponding with R and P (CPPR, CPPP) was markedly reduced, averaging 79.1 +/- 15.9mmHg, 50.9 +/- 12.7mmHg, respectively. Both ORA and ORB in group I were higher, and both CPPR and CPPP in group 1 were lower, than in group II. Statistically, this is significant. Both R and P in Group I tended to be higher than in group II. This has no statistical significance. CBF in all 5 cases averaged 34.8 +/- 8.4ml/100g/min. No significant difference in the impairment of CBF was found between both groups. RI cisternography showed delayed clearance in all 9 cases.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Carcinoma/diagnóstico , Pressão Intracraniana , Neoplasias Meníngeas/diagnóstico , Adulto , Idoso , Carcinoma/fisiopatologia , Circulação Cerebrovascular , Feminino , Humanos , Masculino , Neoplasias Meníngeas/fisiopatologia , Pessoa de Meia-Idade
20.
Eksp Onkol ; 10(2): 66-9, 1988.
Artigo em Russo | MEDLINE | ID: mdl-3391125

RESUMO

A model of the Markov stochastic reproduction and death process is studied as applied to the analysis of time intervals necessary for the experimental tumours to achieve the fixed size. The analysis results have shown nonstationarity of the tumour growth processes during early stages of the tumour development. The presence of such a nonstationarity makes the experimental data interpretation difficult when applying the traditional approach to the tumour cell population kinetics.


Assuntos
Modelos Biológicos , Neoplasias Experimentais/fisiopatologia , Animais , Neoplasias Brônquicas/fisiopatologia , Carcinoma/fisiopatologia , Ciclo Celular , Cadeias de Markov , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos CBA
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA